Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 210

The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.

Small Molecule NF-κB Pathway Inhibitors in Clinic

Open access
Ramadass, Venkataramanan, Vaiyapuri, Thamilselvan, Tergaonkar, Vinay · 2020 · International Journal of Molecular Sciences

Abstract

Nuclear factor kappa B (NF-κB) signaling is implicated in all major human chronic diseases, with its role in transcription of hundreds of gene well established in the literature. This has propelled research into targeting the NF-κB pathways for modulating expression of those genes and the diseases mediated by them. In-spite of the critical, but often promiscuous role played by this pathway and the inhibition causing adverse drug reaction, currently many biologics, macromolecules, and small molecules that modulate this pathway are in the market or in clinical trials. Furthermore, many marketed drugs that were later found to also have NF-κB targeting activity were repurposed for new therapeutic interventions. Despite the rising importance of biologics in drug discovery, small molecules got around 76% of US-FDA (Food and Drug Administration-US) approval in the last decade. This encouraged us to review information regarding clinically relevant small molecule inhibitors of the NF-κB pathway from cell surface receptor stimulation to nuclear signaling. We have also highlighted the underexplored targets in this pathway that have potential to succeed in clinic.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/ijms21145164

Cites

13 of 13 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 13 references

Research works printed but not linked: 150

  1. Sen, 1986, Multiple nuclear factors interact with the immunoglobulin enhancer sequences, Cell, 46, 705, 10.1016/0092-8674(86)90346-6 · DOI · Paper page
  2. Ang, 2007, Notch and NFkappaB signaling pathways: Do they collaborate in normal vertebrate brain development and function?, Bioessays, 29, 1039, 10.1002/bies.20647 · DOI
  3. Correa, 2005, Zebrafish IkappaB kinase 1 negatively regulates NF-kappaB activity, Curr. Biol., 15, 1291, 10.1016/j.cub.2005.06.023 · DOI
  4. Garbati, 2011, Inhibition of NF-kB signaling as a strategy in disease therapy, NF-kB in Health and Disease. Current Topics in Microbiology and Immunology, Volume 349, 245
  5. Chew, 2018, Noncoding RNAs: Master regulators of inflammatory signaling, Trends Mol. Med., 24, 66, 10.1016/j.molmed.2017.11.003 · DOI · Paper page
  6. Li, 2016, Activation of mutant TERT promoter by RAS-ERK signaling is a key step in malignant progression of BRAF-mutant human melanomas, Proc. Natl. Acad. Sci. USA, 113, 14402, 10.1073/pnas.1611106113 · DOI
  7. Ozturk, M.B., Li, Y., and Tergaonkar, V. (2017). Current insights to regulation and role of telomerase in human diseases. Antioxidants, 6. · DOI
  8. Puar, Y.R., Shanmugam, M.K., Fan, L., Arfuso, F., Sethi, G., and Tergaonkar, V. (2018). Evidence for the involvement of the master transcription factor NF-kappaB in cancer initiation and progression. Biomedicines, 6. · DOI · Paper page
  9. Xu, 2018, Structural basis for reactivating the mutant TERT promoter by cooperative binding of p52 and ETS1, Nat. Commun., 9, 3183, 10.1038/s41467-018-05644-0 · DOI
  10. Cildir, 2017, The transcriptional program, functional heterogeneity, and clinical targeting of mast cells, J. Exp. Med., 214, 2491, 10.1084/jem.20170910 · DOI
  11. Khattar, 2019, Rap1 regulates hematopoietic stem cell survival and affects oncogenesis and response to chemotherapy, Nat. Commun., 10, 5349, 10.1038/s41467-019-13082-9 · DOI
  12. Herscovitch, 2006, Inhibitors of NF-kB signaling: 785 and counting, Oncogene, 25, 6887, 10.1038/sj.onc.1209982 · DOI · Paper page
  13. Zhang, 2017, 30 Years of NF-kB: A blossoming of relevance to human pathobiology, Cell, 168, 37, 10.1016/j.cell.2016.12.012 · DOI · Paper page
  14. Hayden, 2012, NF-κB, the first quarter-century: Remarkable progress and outstanding questions, Genes Dev., 26, 203, 10.1101/gad.183434.111 · DOI · Paper page
  15. Sun, 2008, New insights into NF-κB regulation and function, Trends Immunol., 29, 469, 10.1016/j.it.2008.07.003 · DOI · Paper page
  16. Hayden, 2008, Shared principles in NF-κB signaling, Cell, 132, 344, 10.1016/j.cell.2008.01.020 · DOI · Paper page
  17. Vallabhapurapu, 2009, Regulation and function of NF-κB transcription factors in the immune system, Annu. Rev. Immunol., 27, 693, 10.1146/annurev.immunol.021908.132641 · DOI · Paper page
  18. Cildir, 2016, Noncanonical NF-kB Signaling in Health and Disease, Trends Mol. Med., 22, 414, 10.1016/j.molmed.2016.03.002 · DOI · Paper page
  19. Sun, 2012, The noncanonical NF-κB pathway, Immunol. Rev., 246, 125, 10.1111/j.1600-065X.2011.01088.x · DOI · Paper page
  20. Xiao, 2001, NF-κB-inducing kinase regulates the processing of NF-κB2 p100, Mol. Cell, 7, 401, 10.1016/S1097-2765(01)00187-3 · DOI · Paper page
  21. Herrington, 2016, Modulation of NF-κB signaling as a therapeutic target in autoimmunity, J. Biomol. Screen., 21, 223, 10.1177/1087057115617456 · DOI
  22. Fukuoka, M., Yoshioka, K., and Hohjoh, H. (2018). NF-κB activation is an early event of changes in gene regulation for acquiring drug resistance in human adenocarcinoma PC-9 cells. PLoS ONE, 13. · DOI
  23. Wang, 2020, Endocrinotherapy resistance of prostate and breast cancer: Importance of the NF-κB pathway, Int. J. Oncol., 56, 1064
  24. Bennett, 2018, NF-κB in the crosshairs: Rethinking an old riddle, Int. J. Biochem. Cell Biol., 95, 108, 10.1016/j.biocel.2017.12.020 · DOI
  25. Gurevich, 2014, Therapeutic potential of small molecules and engineered proteins, Handb. Exp. Pharmacol., 219, 1, 10.1007/978-3-642-41199-1_1 · DOI
  26. Nwibo, 2015, Small molecule drugs; down but not out: A future for medical research and therapeutics, IOSR JDMS, 14, 70
  27. Talevi, 2015, Multi-target pharmacology: Possibilities and limitations of the “skeleton key approach” from a medicinal chemist perspective, Front. Pharmacol., 6, 205, 10.3389/fphar.2015.00205 · DOI · Paper page
  28. Begalli, F., Bennett, J., Capece, D., Verzella, D., D’Andrea, D., Tornatore, L., and Franzoso, G. (2017). Unlocking the NF-κB Conundrum: Embracing Complexity to Achieve Specificity. Biomedicines, 5. · DOI
  29. Tracey, 2008, Tumor necrosis factor antagonist mechanisms of action: A comprehensive review, Pharmacol. Ther., 117, 244, 10.1016/j.pharmthera.2007.10.001 · DOI · Paper page
  30. Ono, 2020, RANKL biology: Bone metabolism, the immune system, and beyond, Inflamm. Regen., 40, 2, 10.1186/s41232-019-0111-3 · DOI · Paper page
  31. Pileri, 2017, Understanding CD30 biology and therapeutic targeting: A historical perspective providing insight into future directions, Blood Cancer J., 7, e603, 10.1038/bcj.2017.85 · DOI · Paper page
  32. Porter, 2019, Small molecules that inhibit TNF signalling by stabilising an asymmetric form of the trimer, Nat. Commun., 10, 1
  33. Anwar, 2019, Recent clinical trends in Toll-like receptor, Med. Res. Rev., 39, 1053, 10.1002/med.21553 · DOI · Paper page
  34. Novack, 2003, The IkappaB function of NF-kappaB2 p100 controls stimulated osteoclastogenesis, J. Exp. Med., 198, 771, 10.1084/jem.20030116 · DOI · Paper page
  35. Tyan, 2019, Rebound vertebral fractures in a patient with lung cancer after oncology-dose Denosumab discontinuation: A cautionary tale, MCP IQ O, 3, 235
  36. Jiang, 2019, Development of small-molecules targeting Receptor Activator of Nuclear Factor-κB Ligand (RANKL)—Receptor Activator of Nuclear Factor-κB (RANK) protein–protein interaction by structure-based virtual screening and hit optimization, J. Med. Chem., 62, 5370, 10.1021/acs.jmedchem.8b02027 · DOI
  37. Kaptein, 2018, Potency and selectivity of BTK inhibitors in clinical development for B-cell malignancies, Blood, 132, 1871, 10.1182/blood-2018-99-109973 · doi:10.1182/blood-2018-99-109973
  38. Owen, 2019, Review of Bruton tyrosine kinase inhibitors for the treatment of relapsed or refractory mantle cell lymphoma, Curr. Oncol., 26, e233, 10.3747/co.26.4345 · DOI
  39. Kutsch, 2019, A prospective, open-label, multicenter, phase 2 trial to evaluate the safety and efficacy of the combination of Tirabrutinib (ONO/GS-4059) and Idelalisib with and without Obinutuzumab in patients with relapsed/refractory chronic lymphocytic leukemia (CLL), Blood, 134, 3047, 10.1182/blood-2019-131025 · doi:10.1182/blood-2019-131025
  40. Rule, 2020, Long-term follow-up of patients with mantle cell lymphoma (MCL) treated with the selective Bruton’s tyrosine kinase inhibitor tirabrutinib (GS/ONO-4059), Leukemia Vol., 34, 1458, 10.1038/s41375-019-0658-7 · DOI
  41. (2020, May 06). Sanofi Brain-Penetrant BTK Inhibitor Meets Primary Endpoint of Phase 2 Trial in Relapsing Multiple Sclerosis. Available online: https://www.sanofi.com/en/media-room/press-releases/2020/2020-02-06-07-00-00.
  42. Chee, 2013, Phase II study of Dasatinib (BMS-354825) in patients with metastatic adenocarcinoma of the pancreas, Oncologist, 18, 1091, 10.1634/theoncologist.2013-0255 · DOI
  43. Tsou, 2014, Cellular Mechanisms of Tissue Fibrosis. 8. Current and future drug targets in fibrosis: Focus on Rho GTPase-regulated gene transcription, Am. J. Physiol. Cell Physiol., 307, C2, 10.1152/ajpcell.00060.2014 · DOI
  44. Levy, 2019, Five Ibrutinib-associated side effects that all clinicians should be aware of, Acta Haematol., 141, 254, 10.1159/000497356 · doi:10.1159/000497356
  45. Conchon, 2011, Dasatinib - clinical trials and management of adverse events in imatinib resistant/intolerant chronic myeloid leukemia, Rev. Bras. Hematol. Hemoter., 33, 131, 10.5581/1516-8484.20110034 · DOI
  46. Nagane, 2019, Phase 1/2 study of Tirabrutinib (ONO/GS-4059), a next-generation Bruton’s Tyrosine Kinase (BTK) inhibitor, monotherapy in patients with relapsed/refractory Primary Central Nervous System Lymphoma (PCNSL), Blood, 134, 1586, 10.1182/blood-2019-123362 · doi:10.1182/blood-2019-123362
  47. Song, 2019, Safety and efficacy of Orelabrutinib monotherapy in Chinese patients with relapsed or refractory mantle celllLymphoma: A multicenter, open-label, phase II study, Blood, 134, 755, 10.1182/blood-2019-126305 · doi:10.1182/blood-2019-126305
  48. Catlett, I.M., Nowak, M., Kundu, S., Zheng, N., Liu, A., He, B., Girgis, I.G., and Grasela, D.M. (2020). Safety, pharmacokinetics and pharmacodynamics of branebrutinib (BMS-986195), a covalent, irreversible inhibitor of Bruton’s tyrosine kinase: Randomised phase I, placebo-controlled trial in healthy participants. Br. J. Clin. Pharmacol. · DOI
  49. Kumagai, 2019, FRI0156 a phase 1, single and multiple ascending dose study of TAS5315—A novel highly selective inhibitor of Bruton’s tyrosine kinase—in healthy male volunteers, Ann. Rheum. Dis., 78, 750
  50. Lee, 2017, Safety, pharmacokinetics, and pharmacodynamics of BMS-986142, a novel reversible BTK inhibitor, in healthy participants, Eur. J. Clin. Pharmacol., 73, 689, 10.1007/s00228-017-2226-2 · DOI
  51. Cohen, S.B. (2019, January 10). Efficacy and safety of Fenebrutinib, a BTK inhibitor, compared to placebo in rheumatoid arthritis patients with active disease despite TNF inhibitor treatment: Randomized, double blind, phase 2 study. Proceedings of the American College of Rheumatology, Atlanta, GA, USA.
  52. Jurczak, W.R., Townsend, W., Tucker, D., Sarholz, B., Scheele, J., Gribben, J., and Zinzani, P.L. (2018, January 19–23). PDPhase I/II, first in human trial with M7583, a Bruton’s tyrosine kinase inhibitor (BTKi), in patients with B cell malignancies. Proceedings of the European Society for Medical Oncology (ESMO) congress, Munich, Germany. · DOI
  53. Danto, 2019, Safety, tolerability, pharmacokinetics, and pharmacodynamics of PF-06650833, a selective interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitor, in single and multiple ascending dose randomized phase 1 studies in healthy subjects, Arthritis Res. Ther., 21, 269, 10.1186/s13075-019-2008-6 · DOI
  54. Younes, 2019, Phase 1 dose-finding study investigating CA-4948, an IRAK4 kinase inhibitor, in patients with R/R NHL: Report of initial efficacy and updated safety information, Blood, 134, 5327, 10.1182/blood-2019-131851 · doi:10.1182/blood-2019-131851
  55. Rasco, 2019, A phase I study of a novel IAP inhibitor APG-1387 as a monotherapy or in combination with pembrolizumab in treatments of patients with advanced solid tumors, J. Clin. Oncol., 37, 3125, 10.1200/JCO.2019.37.15_suppl.3125 · doi:10.1200/jco.2019.37.15_suppl.3125
  56. Pemmaraju, 2019, Final results of phase 2 clinical trial of LCL161, a novel oral SMAC mimetic/IAP antagonist, for patients with intermediate to high risk myelofibrosis, Blood, 134, 555, 10.1182/blood-2019-130046 · DOI
  57. Mita, 2020, A phase I study of ASTX660, an antagonist of inhibitors of apoptosis proteins, in adults with advanced cancers or lymphoma, Clin. Cancer Res., 26, 2819, 10.1158/1078-0432.CCR-19-1430 · DOI
  58. Rhyasen, 2015, IRAK signalling in cancer, Br. J. Cancer, 112, 232, 10.1038/bjc.2014.513 · DOI · Paper page
  59. Wang, 2009, IRAK-4 inhibitors for inflammation, Curr. Top. Med. Chem., 9, 724, 10.2174/156802609789044407 · DOI
  60. Singer, 2018, Inhibition of interleukin-1 receptor-associated kinase 1 (IRAK1) as a therapeutic strategy, Oncotarget, 9, 33416, 10.18632/oncotarget.26058 · DOI
  61. (2020, May 05). Press Release on CU-4948 Phase 1 Study. Available online: http://investors.curis.com/2019-12-06-Curis-Provides-First-Ever-Demonstration-that-Targeting-IRAK4-in-Patients-with-Relapsed-Refractory-Non-Hodgkins-Lymphoma-Results-in-Anti-Cancer-Activity-in-Ongoing-Phase-1-Study.
  62. Ozes, 1999, NF-kappaB activation by tumour necrosis factor requires the Akt serine-threonine kinase, Nature, 401, 82, 10.1038/43466 · DOI · Paper page
  63. Reddy, 1997, Phosphatidylinositol 3-kinase in interleukin 1 signaling. Physical interaction with the interleukin 1 receptor and requirement in NFkappaB and AP-1 activation, J. Biol. Chem., 272, 29167, 10.1074/jbc.272.46.29167 · DOI · Paper page
  64. Fruman, 2014, PI3K and cancer: Lessons, challenges and opportunities, Nat. Rev. Drug Discov., 13, 140, 10.1038/nrd4204 · DOI · Paper page
  65. Ghoneum, A., and Said, N. (2019). PI3K-AKT-mTOR and NFkappaB pathways in ovarian cancer: Implications for targeted therapeutics. Cancers, 11. · DOI · Paper page
  66. Pacold, 2000, Crystal structure and functional analysis of Ras binding to its effector phosphoinositide 3-kinase gamma, Cell, 103, 931, 10.1016/S0092-8674(00)00196-3 · DOI · Paper page
  67. Guo, 2015, The PI3K/AKT pathway and renal cell carcinoma, J. Genet. Genomics, 42, 343, 10.1016/j.jgg.2015.03.003 · DOI · Paper page
  68. Yang, 2019, Targeting PI3K in cancer: Mechanisms and advances in clinical trials, Mol. Cancer, 18, 26, 10.1186/s12943-019-0954-x · DOI · Paper page
  69. Guo, 2019, Recent Advance of Akt Inhibitors in Clinical Trials, Chemistry Select, 4, 9040
  70. Mayer, 2016, The PI3K/AKT pathway as a target for cancer treatment, Annu. Rev. Med., 67, 11, 10.1146/annurev-med-062913-051343 · DOI · Paper page
  71. Michie, J., Kearney, C.J., Hawkins, E.D., Silke, J., and Oliaro, J. (2020). The immuno-modulatory effects of inhibitor of apoptosis protein antagonists in cancer immunotherapy. Cells, 9. · DOI
  72. Zhang, 2019, Ubiquitin ligases cIAP1 and cIAP2 limit cell death to prevent inflammation, Cell Rep., 27, 2679.e2673, 10.1016/j.celrep.2019.04.111 · DOI
  73. Ea, 2006, Activation of IKK by TNFalpha requires site-specific ubiquitination of RIP1 and polyubiquitin binding by NEMO, Mol. Cell, 22, 245, 10.1016/j.molcel.2006.03.026 · DOI · Paper page
  74. Guicciardi, M.E., Werneburg, N.W., Bronk, S.F., Franke, A., Yagita, H., Thomas, G., and Gores, G.J. (2014). Cellular inhibitor of apoptosis (cIAP)-mediated ubiquitination of phosphofurin acidic cluster sorting protein 2 (PACS-2) negatively regulates tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) cytotoxicity. PLoS ONE, 9. · DOI
  75. Sun, 2014, Potent and selective small-molecule inhibitors of cIAP1/2 proteins reveal that the binding of Smac mimetics to XIAP BIR3 is not required for their effective induction of cell death in tumor cells, ACS Chem. Biol., 9, 994, 10.1021/cb400889a · DOI
  76. (2020, May 06). EMA grants Orphan Drug Designation to Debiopharm International SA’sIAP inhibitor Debio 1143 in the Treatment of Ovarian Cancer. Available online: https://www.debiopharm.com/drug-development/press-releases/ema-grants-orphan-drug-designation-to-debiopharm-international-sas-iap-inhibitor-debio-1143-in-the-treatment-of-ovarian-cancer/.
  77. Prescott, J.A., and Cook, S.J. (2018). Targeting IKKβ in cancer: Challenges and opportunities for the therapeutic utilisation of IKKβ inhibitors. Cell, 7. · DOI
  78. Xu, 2009, A ubiquitin replacement strategy in human cells reveals distinct mechanisms of IKK activation by TNFalpha and IL-1beta, Mol. Cell, 36, 302, 10.1016/j.molcel.2009.10.002 · DOI · Paper page
  79. Wang, 2001, TAK1 is a ubiquitin-dependent kinase of MKK and IKK, Nature, 412, 346, 10.1038/35085597 · DOI · Paper page
  80. Weber, 2000, Suppression of NF-κB activity by sulfasalazine is mediated by direct inhibition of IκB kinases α and β, Gastroenterology, 119, 1209, 10.1053/gast.2000.19458 · DOI · Paper page
  81. Yin, 1998, The anti-inflammatory agents aspirin and salicylate inhibit the activity of I(kappa)B kinase-beta, Nature, 396, 77, 10.1038/23948 · DOI · Paper page
  82. Goldfine, 2008, Use of Salsalate to Target Inflammation in the Treatment of Insulin Resistance and Type 2 Diabetes, Clin. Transl. Sci., 1, 36, 10.1111/j.1752-8062.2008.00026.x · DOI · Paper page
  83. Sepulveda, 2007, Amelioration of chronic murine colitis by peptide-mediated transduction of the IkB kinase inhibitor NEMO binding domain peptide, J. Immunol., 179, 7852, 10.4049/jimmunol.179.11.7852 · DOI
  84. Rhodes, 2018, Cell-permeable bicyclic peptidyl inhibitors against NEMO-IκB kinase interaction directly from a combinatorial library, J. Am. Chem. Soc., 140, 12102, 10.1021/jacs.8b06738 · DOI
  85. Verhelst, 2013, IκB kinase ε (IKKε): A therapeutic target in inflammation and cancer, Biochem. Pharmacol., 85, 873, 10.1016/j.bcp.2013.01.007 · DOI
  86. Hovstadius, 2002, A Phase I study of CHS 828 in patients with solid tumor malignancy, Clin. Cancer Res., 8, 2843
  87. Grothe, 2017, IkappaB kinase inhibition as a potential treatment of osteoarthritis—Results of a clinical proof-of-concept study, Osteoarthr. Cartilage, 25, 46, 10.1016/j.joca.2016.08.010 · DOI
  88. Stansfield, 2017, New Substituted Cyanoindoline Derivatives as MAP3K14 Kinase Inhibitors for the Treatment of Cancer and Autoimmune Disorders, ACS Med. Chem. Lett., 8, 908, 10.1021/acsmedchemlett.7b00330 · doi:10.1021/acsmedchemlett.7b00330
  89. Pohl, 2019, Cellular quality control by the ubiquitin-proteasome system and autophagy, Science, 366, 818, 10.1126/science.aax3769 · DOI · Paper page
  90. Thibaudeau, 2019, A Practical Review of Proteasome Pharmacology, Pharmacol. Rev., 71, 170, 10.1124/pr.117.015370 · DOI · Paper page
  91. Clague, 2015, The demographics of the ubiquitin system, Trends Cell Biol., 25, 417, 10.1016/j.tcb.2015.03.002 · DOI · Paper page
  92. Myung, 2001, The ubiquitin-proteasome pathway and proteasome inhibitors, Med. Res. Rev., 21, 245, 10.1002/med.1009 · DOI · Paper page
  93. Ohtake, 2017, The emerging complexity of ubiquitin architecture, J. Biochem., 161, 125
  94. Meyer, 2014, Enhanced protein degradation by branched ubiquitin chains, Cell, 157, 910, 10.1016/j.cell.2014.03.037 · DOI · Paper page
  95. Ohtake, 2016, The K48-K63 branched ubiquitin chain regulates NF-kappaB signaling, Mol. Cell, 64, 251, 10.1016/j.molcel.2016.09.014 · DOI · Paper page
  96. Sherman, D.J., and Li, J. (2020). Proteasome inhibitors: Harnessing proteostasis to combat disease. Molecules, 25. · DOI
  97. Huang, 2014, Efficacy of therapy with bortezomib in solid tumors: A review based on 32 clinical trials, Future Oncol. Lond. Engl., 10, 1795, 10.2217/fon.14.30 · DOI
  98. Gupta, 2019, Clinical Pharmacology of Ixazomib: The First Oral Proteasome Inhibitor, Clin. Pharmacokinet., 58, 431, 10.1007/s40262-018-0702-1 · DOI
  99. Perel, 2016, Carfilzomib (Kyprolis): A novel proteasome inhibitor for relapsed and/or refractory multiple myeloma, P T, 41, 303
  100. Camargo, M., Farouk, S., and Campbell, K. (2017, January 1–3). Help or hindrance? An atypical presentation of Carfilzomib-induced nephrotoxicity. Proceedings of the 19th International Conference on Dialysis, Advances in CKD, Las Vegas, NV, USA.
  101. Roth, 2019, EORTC 1709/CCTG CE.8: A phase III trial of marizomib in combination with standard temozolomide-based radiochemotherapy versus standard temozolomide-based radiochemotherapy alone in patients with newly diagnosed glioblastoma, J. Clin. Oncol., 37, TPS2072, 10.1200/JCO.2019.37.15_suppl.TPS2072 · doi:10.1200/jco.2019.37.15_suppl.tps2072
  102. Cvek, 2008, The value of proteasome inhibition in cancer: Can the old drug, disulfiram, have a bright new future as a novel proteasome inhibitor?, Drug Discov. Today, 13, 716, 10.1016/j.drudis.2008.05.003 · DOI
  103. Ekinci, 2019, Repurposing Disulfiram as An Anti-Cancer Agent: Updated Review on Literature and Patents, Recent Pat. Anti-Canc., 14, 113
  104. Morgan, 2006, Bortezomib (Velcadetrade mark) in the treatment of multiple myeloma, Ther. Clin. Risk Manag., 2, 271, 10.2147/tcrm.2006.2.3.271 · DOI · Paper page
  105. Siegel, 2013, From clinical trials to clinical practice: Single-agent carfilzomib adverse events and their management in patients with relapsed and/or refractory multiple myeloma, Ther. Adv. Hematol., 4, 354, 10.1177/2040620713511176 · DOI
  106. McBride, 2013, The side effect profile of Carfilzomib: From clinical trials to clinical practice, J. Adv. Pract. Oncol., 4, 22
  107. Potts, 2011, Marizomib, a proteasome inhibitor for all seasons: Preclinical profile and a framework for clinical trials, Curr. Cancer Drug Targets, 11, 254, 10.2174/156800911794519716 · DOI · Paper page
  108. Rajan, 2016, New investigational drugs with single-agent activity in multiple myeloma, Blood Cancer J., 6, e451, 10.1038/bcj.2016.53 · DOI
  109. Swords, 2017, Expanded safety analysis of pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukemia and myelodysplastic syndromes, Blood Cancer J., 7, e520, 10.1038/bcj.2017.1 · DOI
  110. Soucy, 2010, The NEDD8 Conjugation Pathway and Its Relevance in Cancer Biology and Therapy, Genes Cancer, 1, 708, 10.1177/1947601910382898 · DOI · Paper page
  111. Zhou, 2019, Neddylation: A novel modulator of the tumor microenvironment, Mol. Cancer, 18, 77, 10.1186/s12943-019-0979-1 · DOI · Paper page
  112. LianLiang, 2013, KPNB1, XPO7 and IPO8 mediate the translocation of NF-κB/p65 into the nucleus, Traffic, 14, 1132, 10.1111/tra.12097 · DOI
  113. Fagerlund, 2005, NF-{kappa} B is transported into the nucleus by importin {alpha}3 and importin {alpha}4, J. Biol. Chem., 280, 15942, 10.1074/jbc.M500814200 · DOI · Paper page
  114. Viatour, 2005, Phosphorylation of NF-kappaB and IkappaB proteins: Implications in cancer and inflammation, Trends Biochem. Sci., 30, 43, 10.1016/j.tibs.2004.11.009 · DOI · Paper page
  115. Huang, 2010, Posttranslational modifications of NF-kappaB: Another layer of regulation for NF-kappaB signaling pathway, Cell Signal, 22, 1282, 10.1016/j.cellsig.2010.03.017 · DOI · Paper page
  116. Kim, 2012, New molecular bridge between RelA/p65 and NF-κB target genes via histone acetyltransferase TIP60 cofactor, J. Biol. Chem., 7780-91, 287
  117. Kiernan, 2003, Post-activation turn-off of NF-kappa B-dependent transcription is regulated by acetylation of p65, J. Biol. Chem., 278, 2758, 10.1074/jbc.M209572200 · DOI · Paper page
  118. Hajmirza, A., Emadali, A., Gauthier, A., Casasnovas, O., Gressin, R., and Callanan, M.B. (2018). BET family protein BRD4: An emerging actor in NFκB signaling in inflammation and cancer. Biomedicines, 6. · DOI
  119. Mathew, C., and Ghildyal, R. (2017). CRM1 inhibitors for antiviral therapy. Front. Microbiol., 8. · doi:10.3389/fmicb.2017.01171
  120. Bachelerie, 1997, Evidence for a role of CRM1 in signal-mediated nuclear protein export, Science, 278, 141, 10.1126/science.278.5335.141 · DOI · Paper page
  121. Wolff, 1997, Leptomycin B is an inhibitor of nuclear export: Inhibition of nucleo-cytoplasmic translocation of the human immunodeficiency virus type 1 (HIV-l) Rev protein and Rev-dependent mRNA, Chem. Biol., 4, 139, 10.1016/S1074-5521(97)90257-X · DOI · Paper page
  122. Kosyna, F.K., and Depping, R. (2018). Controlling the gatekeeper: Therapeutic targeting of nuclear transport. Cells, 7. · DOI
  123. Sadowski, 2018, Phase II study of the oral selective inhibitor of nuclear export (SINE) KPT-335 (verdinexor) in dogs with lymphoma, BMC Vet. Res., 14, 1, 10.1186/s12917-018-1587-9 · doi:10.1186/s12917-018-1587-9
  124. Wang, 2019, The past, present, and future of CRM1/XPO1 inhibitors, Stem Cell Investig., 6, 6, 10.21037/sci.2019.02.03 · DOI
  125. Gavriatopoulou, M., Chari, A., Chen, C., Bahlis, N., Vogl, D.T., Jakubowiak, A., Dingli, D., Cornell, R.F., Hofmeister, C.C., and Siegel, D. (2020). Integrated safety profile of selinexor in multiple myeloma: Experience from 437 patients enrolled in clinical trials. Leukemia. · DOI
  126. Bubna, 2015, Vorinostat-An Overview, Indian J. Dermatol., 60, 419, 10.4103/0019-5154.160511 · DOI
  127. Liu, 2016, Efficacy and safety of Panobinostat in relapsed or/and refractory multiple myeloma: Meta analyses of clinical trials and systematic review, Sci. Rep., 6, 27361, 10.1038/srep27361 · DOI
  128. Zhang, 2018, Exploratory clinical study of chidamide, an oral subtype-selective histone deacetylase inhibitor, in combination with exemestane in hormone receptor-positive advanced breast cancer, Chin. J. Cancer Res., 30, 605, 10.21147/j.issn.1000-9604.2018.06.05 · DOI
  129. Khan, 2012, Azacitidine in the management of patients with myelodysplastic syndromes, Ther. Adv. Hematol., 3, 355, 10.1177/2040620712464882 · DOI
  130. Saba, 2007, Decitabine in the treatment of myelodysplastic syndromes, Ther. Clin. Risk Manag., 3, 807
  131. Wagstaff, 2012, Ivermectin is a specific inhibitor of importin α/β-mediated nuclear import able to inhibit replication of HIV-1 and dengue virus, Biochem. J., 443, 851, 10.1042/BJ20120150 · DOI · Paper page
  132. Soderholm, 2011, Importazole, a small molecule inhibitor of the Transport Receptor Importin-β, ACS Chem. Biol., 6, 700, 10.1021/cb2000296 · DOI · Paper page
  133. Lin, 1995, Inhibition of nuclear translocation of transcription factor NF-κB by a synthetic peptide containing a cell membrane-permeable motif and nuclear localization sequence, J. Biol. Chem., 270, 14255, 10.1074/jbc.270.24.14255 · DOI · Paper page
  134. Wang, 2011, A Cell-penetrating peptide suppresses inflammation by inhibiting NF-κB signaling, Mol. Ther., 19, 1849, 10.1038/mt.2011.82 · DOI
  135. Perkins, 2008, Regulation of the RelA (p65) transactivation domain, Biochem. Soc. Trans., 36, 603, 10.1042/BST0360603 · DOI
  136. Lecoq, 2017, Structural characterization of interactions between transactivation domain 1 of the p65 subunit of NF-kappaB and transcription regulatory factors, Nucleic Acids Res., 45, 5564, 10.1093/nar/gkx146 · DOI
  137. Rothgiesser, K.M., Fey, M., and Hottiger, M.O. (2010). Acetylation of p65 at lysine 314 is important for late NF-kappaB-dependent gene expression. BMC Genom., 11. · DOI
  138. Drahos, 2020, Current trends in the analysis of post-translational modifications, Chromatographia, 83, 1, 10.1007/s10337-019-03796-9 · DOI
  139. Yuksel, 2003, Gabexate mesilate, a synthetic protease inhibitor, inhibits lipopolysaccharide-induced tumor necrosis factor-alpha production by inhibiting activation of both nuclear factor-kappaB and activator protein-1 in human monocytes, J. Pharmacol. Exp. Ther., 305, 298, 10.1124/jpet.102.041988 · DOI
  140. Hoffman, 2019, Vamorolone trial in Duchenne muscular dystrophy shows dose-related improvement of muscle function, Neurology, 93, e1312, 10.1212/WNL.0000000000008168 · DOI
  141. Zimmermann, 2018, The immunomodulatory effects of macrolides—A systematic review of the underlying mechanisms, Front. Immunol., 9, 302, 10.3389/fimmu.2018.00302 · DOI · Paper page
  142. Sugawara, 2016, Non-antibiotic 12-membered macrolides: Design, synthesis and biological evaluation in a cigarette-smoking model, J. Antibiot. (Tokyo), 69, 319, 10.1038/ja.2015.91 · doi:10.1038/ja.2015.91
  143. Niloo, 2015, Plant polyphenols as inhibitors of NF-κB induced cytokine production—a potential anti-inflammatory treatment for Alzheimer’s disease?, Front. Mol. Neurosci., 8, 24
  144. Shimizu, 2019, Anti-inflammatory action of Curcumin and its use in the treatment of lifestyle-related diseases, Eur. Cardiol., 14, 117, 10.15420/ecr.2019.17.2 · DOI
  145. Sharifi-Rad, M., Pezzani, R., Redaelli, M., Zorzan, M., Imran, M., Ahmed Khalil, A., Salehi, B., Sharopov, F., Cho, W.C., and Sharifi-Rad, J. (2020). Preclinical activities of Epigallocatechin gallate in signaling pathways in cancer. Molecules, 25. · DOI
  146. Xie, 2020, Iguratimod as a new drug for rheumatoid arthritis: Current landscape, Front. Pharmacol., 11, 73, 10.3389/fphar.2020.00073 · doi:10.3389/fphar.2020.00073
  147. Li, 2018, Novel disease-modifying anti-rheumatic drug iguratimod suppresses chronic experimental autoimmune encephalomyelitis by down-regulating activation of macrophages/microglia through an NF-κB pathway, Sci. Rep., 8, 1933, 10.1038/s41598-018-20390-5 · DOI
  148. Ehsanian, 2011, Beyond DNA binding—A review of the potential mechanisms mediating quinacrine’s therapeutic activities in parasitic infections, inflammation, and cancers, Cell Commun. Signal, 9, 13, 10.1186/1478-811X-9-13 · DOI
  149. Martin, 2001, Dimethylfumarate inhibits Tumor-Necrosis-Factor-induced CD62E expression in an NF-κB-dependent manner, J. Invest. Dermatol., 117, 1363, 10.1046/j.0022-202x.2001.01576.x · DOI
  150. Yan, B., Kuick, C.H., Lim, M., Venkataraman, K., Tennakoon, C., Loh, E., Lian, D., Leong, M.Y., Lakshmanan, M., and Tergaonkar, V. (2014). Platform comparison for evaluation of ALK protein immunohistochemical expression, genomic copy number and hotspot mutation status in neuroblastomas. PLoS ONE, 9. · DOI

Cited by

See all 210

Metadata

Authors
Ramadass, V., Vaiyapuri, T., & Tergaonkar, V.
Venue
International Journal of Molecular Sciences
Publisher
MDPI AG
Published
2020-07-21
Volume
21
Issue
14
Pages
5164
ISSN
1422-0067 (ISSN-L)
OpenAlex
W3044714181
Cited by
210
References
13
FWCI
8.56
Type
journal article
Language
en
Open access
gold
Funders
National Research Foundation Singapore (NRF-CRP17-2017-02)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Small Molecule NF-κB Pathway Inhibitors in Clinic. https://app.cochat.ai/papers/10.3390/ijms21145164
The paper
Ramadass, V., Vaiyapuri, T., & Tergaonkar, V. (2020). Small Molecule NF-κB Pathway Inhibitors in Clinic. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms21145164

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.